Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Published:2013-04-11 Issue:15 Volume:121 Page:2864-2874
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fowler Daniel H.¹,Mossoba Miriam E.¹,Steinberg Seth M.²,Halverson David C.¹,Stroncek David³,Khuu Hahn M.³,Hakim Frances T.¹,Castiello Luciano³,Sabatino Marianna³,Leitman Susan F.³,Mariotti Jacopo¹,Gea-Banacloche Juan C.¹,Sportes Claude¹,Hardy Nancy M.¹,Hickstein Dennis D.¹,Pavletic Steven Z.¹,Rowley Scott⁴,Goy Andre⁴,Donato Michele⁴,Korngold Robert⁴,Pecora Andrew⁴,Levine Bruce L.⁵,June Carl H.⁵,Gress Ronald E.¹,Bishop Michael R.¹

Affiliation:

1. Experimental Transplantation and Immunology Branch, National Cancer Institute,

2. Biostatistics and Data Management, National Cancer Institute, and

3. Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD;

4. The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and

5. University of Pennsylvania, Abramson Family Cancer Research Center, Philadelphia, PA

Abstract

Key Points Donor T-Rapa cells were composed of Th1 and Th2 effectors with a reproducible gene expression profile. Preemptive T-Rapa donor lymphocyte infusion was safe and associated with donor engraftment without excessive GVHD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/15/2864/1364885/2864.pdf

Reference50 articles.

1. Non myeloablative “mini transplants”.;Giralt;Cancer Treat Res,1999

2. Review of “minitransplantation”: nonmyeloablative allogeneic hematopoietic stem cell transplantation.;Georges;Int J Hematol,2003

3. Reduced mortality after allogeneic hematopoietic-cell transplantation.;Gooley;N Engl J Med,2010

4. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.;Kahl;Blood,2007

5. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.;Baron;Blood,2004

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders;EMBO Molecular Medicine;2022-03-17

2. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor;Frontiers in Immunology;2021-10-05

3. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies;Journal of Clinical Oncology;2021-02-10

4. Potency analysis of cellular therapies: the role of molecular assays;Principles of Translational Science in Medicine;2021

5. Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance;Blood;2020-07-23